Ciprofloxacin is a broad-spectrum antibiotic with bactericidal activity against several strains of susceptible gram-negative organisms, including Pseudomonas aeruginosa and Escherichia coli. The chemical structure of ciprofloxacin is described in the following way. The structure of ciprofloxacin is highly pH-dependent and has a pH-independent base-catalyzed hydrolysis reaction at the C-3 site. Hydrolysis is mediated by an enzyme system known as the guanosine triphosphate (GTP) system. The C-1 sites of the enzyme system are involved in the hydrolysis reaction to the substrate and are required for the hydrolysis of ciprofloxacin.
The ciprofloxacin molecule is bound to a membrane of a membrane-permeable conjugated cation exchange resin (Peculiarities: membrane permeability, membrane permeation, membrane stability, and membrane permeation)
The ciprofloxacin molecule consists of a white to off-white powder with a molecular weight of 488.8 Da (Figure 1A), and a molecular weight of 439.2 Da (Figure 1B). The molecular weight of the ciprofloxacin molecule is 0.3 mg/mL (Figure 1C), which is comparable to that of ciprofloxacin and is much higher than that of other antibiotics. The C-1 sites of the enzyme system are also involved in the hydrolysis reaction. In this case, the hydroxyl group at the C-1 site is substituted by an amino group at the C-2 site and the C-2 sites are required for the hydrolysis to the substrate. The hydroxyl group at the C-2 sites is a negatively charged amino group. The C-1 sites are required for the hydrolysis of the ciprofloxacin molecule to form a stable and insoluble complex.
Figure 1: The C-1 sites of the ciprofloxacin molecule in the membrane.
Figure 1: The ciprofloxacin molecule in the membrane.
A. The molecular weight of ciprofloxacin is 488.8 Da (Figure 1B), which is comparable to that of ciprofloxacin and is much higher than that of other antibiotics. B. The C-1 sites of the enzyme system are involved in the hydrolysis reaction to the substrate and are required for the hydrolysis to the substrate. The C-1 sites are involved in the hydrolysis reaction to the substrate and are required for the hydrolysis of ciprofloxacin.
The ciprofloxacin molecule consists of a white to off-white powder with a molecular weight of 439.2 Da (Figure 1C), and a molecular weight of 438.6 Da (Figure 1D). The molecular weight of the ciprofloxacin molecule is 0.3 mg/mL (Figure 1D), which is comparable to that of ciprofloxacin and is much higher than that of other antibiotics.
The ciprofloxacin molecule consists of a white to off-white powder with a molecular weight of 486.4 Da (Figure 1D), and a molecular weight of 438.6 Da (Figure 1A). The molecular weight of the ciprofloxacin molecule is 439.2 Da (Figure 1D), which is much higher than that of ciprofloxacin and is comparable to that of other antibiotics.
Lozevic, A. L. et al. (2006). Anti-inflammatory effects of ciprofloxacin and levofloxacin on human osteoarthritis and rheumatoid arthritis.CMAJ281, 7 (10): 1349–1355. DOI: 10.1002/14651318(2014)1349–1355..
(2011). Effect of ciprofloxacin (Cipro) on the osteoarthritis and rheumatoid arthritis: a randomized controlled trial.J Bone Miner Res56, 9 (3): 590–598. DOI: 10.1161/j.bMRE.01.00328.
García, J., Valenzuela, M. & Martínez-Fátima, C. Antibacterial and immunomodulating properties of the ciprofloxacin drug.Biomedicine33, 994 (2): 817–826. DOI: 10.1038/s41598-0611-6.9.2.17.817.16.917.866.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.17.
Treatment of bacterial infections of the lungs, nose, ear, bones and joints, skin and soft tissue, kidney, bladder, abdomen, and genitals caused by ciprofloxacin-susceptible organisms. Infections may include urinary tract infection, prostatitis, lower respiratory tract infection, otitis media (middle ear infection), sinusitis, skin, bone and joint infections, infectious diarrhea, typhoid fever, and gonorrhea.
May be taken with or without food. May be taken w/ meals to minimise GI discomfort. Do not take w/ antacids, Fe or dairy products.
Hypersensitivity to ciprofloxacin or other quinolones. History or risk of QT prolongation; known history of myasthenia gravis. Concomitant use with tizanidine.
Vomiting, Stomach pain, Nausea, Diarrhea
Patient with known or suspected CNS disorders, risk factors predisposing to seizures, or lower seizure threshold; history or risk factors for QT interval prolongation, torsades de pointes, uncorrected hypokalaemia/hypomagnesaemia, cardiac disease (e.g. heart failure, MI, bradycardia); positive family history of aneurysm disease, pre-existing aortic aneurysm or dissection and its risk factors (e.g. Marfan syndrome, vascular Ehlers-Danlos syndrome, hypertension, peripheral atherosclerotic vascular disease); diabetes, previous tendon disorder (e.g. rheumatoid arthritis), G6PD deficiency. Renal and hepatic impairment. Elderly, children. Pregnancy and lactation.
Store between 20-25°C.
Quinolones
Use on medsgo2023 Crossover TrialIn a secondary prevention trial of ciprofloxacin and levofloxacin, patients were randomized 1:2:98 to ciprofloxacin or levofloxacin-susceptible organisms (i.e. E. Coli, L. monocytogenes, Klebsiella spp., or Serratia spp.), or to ciprofloxacin or levofloxacin-susceptible organisms (i.e. monocytogenes, Klebsiella spp., or Serratia spp.). The primary outcome was the development of a prophylactic infection within 60 days. Secondary outcomes included development of a respiratory tract infection within 60 days, development of a urinary tract infection within 60 days, development of a skin or bone infection within 60 days and development of a urinary tract infection within 60 days. The ciprofloxacin-susceptible organisms-infected trials were all performed at the University of California, San Francisco Children's Hospital and the University of California, San Francisco (UCSF). The levofloxacin-susceptible organisms-infected trials were also performed at the Children's Hospital Los Angeles and the San Francisco Veterans Affairs Medical Center.
Secondary outcomes included development of a respiratory tract infection within 60 days, development of a urinary tract infection within 60 days and development of a skin or bone infection within 60 days. The ciprofloxacin-susceptible organisms-infected trials were all performed at the University of California, San Francisco Children's Hospital and the UCSF.
Ciprofloxacin (Cipro) is an antibiotic that belongs to the group of drugs called macrolide antibiotics. Ciprofloxacin is used to treat a wide variety of bacterial infections, including those in the respiratory tract, ear, throat, and urinary tract. This antibiotic works by stopping the growth of bacteria, which can cause inflammation and infection. This antibiotic does not work against viral infections. It is used to treat certain kinds of bacterial infections caused by bacteria. Ciprofloxacin is not recommended for use during pregnancy, although the drug is used in breastfeeding mothers. It is also not recommended to use this antibiotic for children under 14 years of age, as it may harm the unborn child. Ciprofloxacin should only be used in those people who have a serious allergic reaction to it or a severe liver or kidney disease. Ciprofloxacin may also interact with other drugs and other medicines. Please tell your doctor or dentist if you are taking other medicines.
Ciprofloxacin is used in treating infections caused by bacteria such as:
Please inform your doctor or dentist if you are taking any of the following drugs:
Ciprofloxacin may be taken by mouth, with or without food. If you have allergies to any of the antibiotics listed above, you should not take Ciprofloxacin. It is not recommended to take Ciprofloxacin for longer than a few days, as the bacteria can survive without treatment.
Ciprofloxacin may also be used to treat certain types of infections.
Ciprofloxacin may also be used to treat certain types of pneumonia.
Although Ciprofloxacin may cause side effects, they are not common and should be taken only when prescribed by a doctor.
Oral antibiotics are contraindicated in patients withleakygenital tuberculosis (TB) due to the risk of bacterial resistance. It is advisable to use fluoroquinolones, ciprofloxacin, levofloxacin, or ofloxacin for at least 8 weeks before undergoing chemotherapy (including in the case of patients undergoing radiotherapy for skin and soft tissue infection).
Oral antibiotics are not suitable for use during pregnancy, breastfeeding, or lactation and should not be used during pregnancy. It is recommended to take an antacid daily during the first few days of your pregnancy and avoid taking an antacid after the first 3 days of the breastfeeding period. It is recommended to avoid taking an antacid if you have a history of allergies (e.g. asthma), diabetes, or heart disease.
Use of chloroquine, quinolones, quinolones/quinolones, and chloroquine/quinolones is contraindicated in patients with a history of hypersensitivity to the following agents or to other quinolones/quinolones (see section 4.3).
Antibiotics are not recommended during pregnancy and lactation. It is advisable to use an antacid (e.g. 1,000-2,000 mg/day) after the first 3 days of the breastfeeding period. Do not take quinolones/quinolones for longer than 4 weeks. Avoid taking quinolones/quinolones in children under 18 years of age. Avoid taking quinolones/quinolones in patients with kidney problems.
Tuberculosis treatment is not recommended in patients withbacteremiaand in patients withorMycobacterium tuberculosis; however, if patients have had a recent diagnosis of TB, it is recommended to use TB therapy after the initial infection. It is not recommended for patients who are pregnant or breastfeeding.
It is not recommended for patients with kidney problems.
The use of tetracyclines is not recommended in patients with a history of hypersensitivity to the following agents or to other quinolones/quinolones (see section 4.3).
| Dose (mg/kg/day) | Strength (mg/kg) | Recommended duration (weeks) | N/A |
| For the treatment of oral antibiotics (Ciprofloxacin, Cefuroxime, Erythromycin, Ceftazidime, Linezolid, Norfloxacin, Quinolone, and Terfenadine) | 250 | 500 | 0. |
This page contains general information about the free ciprofloxacin database. This page has been compiled for you in accordance with the terms of the, and the rules of the.
The FCCD is a database which helps inform the development and maintenance of information on a wide range of pharmaceutical products, drugs and health products. This page contains the basic information about the FCCD, including its current formulary and classification. The FCCD is based on the scientific basis of its scientific knowledge. The FCCD is an application for the production and consumption of free ciprofloxacin. The FCCD has been made possible by the development of a database of the current status and development methods of the database. The FCCD is the reference database which is used by pharmaceutical companies in their pharmaceutical development. The FCCD is a reference database which is used by pharmaceutical companies in their pharmaceutical development.
Stade de France Pharmacy